Pharma Times
JULY 10, 2025
The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses.
Pharmacy Times
JULY 16, 2025
The shift away from thimerosal may increase the use of single-dose syringes, impacting vaccination practices in various healthcare settings. ACIP's recommendations are increasingly significant for pharmacies, influencing vaccination planning, billing, and patient care activities.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JULY 1, 2025
The vaccine showed a 26.6% higher relative vaccine efficacy compared with the existing option. Across all age groups, risk profiles and vaccination histories, the results were consistently strong. The severity of this past flu season underscores the need for more effective vaccines.” for A/H1N1, 22.2% for B/Victoria.
Pharmacy Times
JULY 16, 2025
ASCO 2025: insights on NALIRIFOX use in metastatic pancreatic ductal adenocarcinoma from the NAPOLI-3 trial. Pharmacy Times. June 5, 2025. Accessed June 23, 2025.
Pharmacy Times
JULY 22, 2025
link] Ewart L, Apostolou A, Briggs SA, et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Commun Med (Lond). 2022;2(1):154. Subscribe Now!
Pharmacy Times
JULY 22, 2025
These deserts reduce access to critical health care services, such as vaccinations, health screenings, and point-of-care testing. The lack of access to immunization services may lead to lower vaccination rates and vulnerabilities to infectious diseases in these communities. Health Aff Sch. 2024;2(4):qxae035. Medicina (Kaunas).
Pharmacy Times
JUNE 27, 2025
Pharmacists are well positioned to perform drug interaction checks, counsel patients on adherence and administration, and coordinate supportive care, including prophylaxis for infections (eg, granulocyte colony-stimulating factor, vaccines). Acalabrutinib plus bendamustine and rituximab may become new standard care for untreated MCL.
Expert insights. Personalized for you.
82 
Let's personalize your content